Loading company…
Ukko uses protein engineering and AI to develop proteins for food and therapeutic applications.
Founded in 2016 and based in Tel Aviv, Israel, Ukko applies computational biology, immunology and protein engineering to develop proteins for food and therapeutic uses. In January 2026, it raised USD 45 million in Series C funding led by Israel Biotech Fund and Sanara Capital, with participation from Khosla Ventures, Leaps by Bayer, Fall Line Capital and other investors. The funding is intended to support clinical trials and development of its programs for peanut allergy and celiac disease.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in